BeiGene (SHA:688235, HKG:6160) expects 2025 revenue to range between 35.2 billion yuan and 38.1 billion yuan on the back of Brukinsa's strong market position in the US and continued expansion in Europe and other key global markets.
Gross margin is projected to be in the mid-range of 80% to 90%, according to a Friday filing with the Shanghai bourse.
Meanwhile, research and development, sales, and administrative expenses are expected to range between 29.5 billion yuan and 31.9 billion yuan.
Shares of the drug company jumped 7% in recent trade on the Shanghai bourse.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。